Posters 647 protect children"s population from side effects of numerous drugs. Aim:To evaluate the use of medical preparation Asthmanol for BA and other respiratory obstructive diseases. Methods:Medical preparation offered by us, Asthmanol, is composed from ecologically pure ingredients. Preparation Asthmanol has passed key stages of pharmaco-epidemiology. We collected data on sex, age, respiratory function and on asthma control questionnaire (ACQ). Results:Of 255 children aged 5-16 years with BA were randomized 1:1 to receive Asthmanol or placebo. Symptomatic medications were provided as rescue medications to both groups. The values of respiratory function before beginning the treatment with Asthmanol were: FEV1 87,5±20,4 and FEF25-75 39,9±32,6. After treatment they were 88,7±13,8 and 58,7±19,5 respectively. We found a improvement in the asthma control questionnaire, with pre-and post values of 22±7,4 and 5,9±7 respectively. Statistically significant improvements were found for the BA group relative to placebo (p=0,047). Conclusion:The results of our study, according to GINA and PRACTALL EAACI/AAAAI guidelines , show that therapy with medication consisting of natural components is an effectiveness in asthmatic children. There was important improvement in the quality of life and in the control of asthma with Asthmanol. LUNG TUBERCULOSIS IN CHILDREN-